Nomura Holdings’s Neurocrine Biosciences NBIX Stock Holding History

Nomura Holdings’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11,500	Closed	-$1.33M	–	2324
2024 Q3	$1.33M	Sell	11,500 -5,300	-32%	-$727K	﹤0.01%	1072
2024 Q2	$2.31M	Buy	+16,800	New	+$2.3M	﹤0.01%	900
2022 Q4	–	Sell	-44,900	Closed	-$4.77M	–	1614
2022 Q3	$4.77M	Sell	44,900 -44,700	-50%	-$4.54M	0.02%	571
2022 Q2	$8.89M	Buy	89,600 +25,800	+40%	+$2.38M	0.03%	378
2022 Q1	$6.1M	Buy	+63,800	New	+$5.41M	0.02%	554
2020 Q3	–	Sell	-80,000	Closed	-$9.77M	–	1398
2020 Q2	$9.77M	Buy	+80,000	New	+$8.84M	0.03%	274
2020 Q1	–	Sell	-30,000	Closed	-$3.22M	–	1130
2019 Q4	$3.22M	Buy	+30,000	New	+$3.14M	0.01%	535
2019 Q3	–	Sell	-20,000	Closed	-$1.7M	–	1335
2019 Q2	$1.7M	Buy	+20,000	New	+$1.64M	0.01%	711

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nomura Holdings's NBIX Position: Q1 2026 in Review

Nomura Holdings reduced its Neurocrine Biosciences (NBIX) stake by 44% in Q1 2026, selling an estimated $439K and leaving 4,200 shares worth $553K. The position accounts for ﹤0.01% of the portfolio, ranked #1331.

Nomura Holdings first reported a position in NBIX in Q2 2013 and has held it in 24 quarters since. The position peaked at $6.99M in Q3 2018. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Nomura Holdings held 4,200 shares of Neurocrine Biosciences worth $553K as of Q1 2026.
Nomura Holdings sold 3,310 Neurocrine Biosciences shares in Q1 2026, an estimated $439K.
Neurocrine Biosciences made up ﹤0.01% of Nomura Holdings's portfolio in Q1 2026, its #1331 holding.
Nomura Holdings first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 24 quarters since.
Nomura Holdings's Neurocrine Biosciences position peaked at $6.99M in Q3 2018.
695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.